Pricing updated 2019-07-17. Prices are subject to change without notice.
Alogliptin is an orally bioavailable dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50 = 6.9 nM) that is selective for DPP-4 over DPP-2, DPP-8, DPP-9, prolyl endopeptidase, fibroblast activation protein (FAP), and tryptase (IC50s = >100,000 nM).1 It does not inhibit cytochrome P450 enzymes and does not block the human ether-a-go-go-related gene (hERG) channel when used at concentrations up to 30 μM.2 Alogliptin inhibits DPP-4 activity in vivo in rats, dogs, and cynomolgus monkeys (EC50s = 3.4, 4.9, and 5.6 ng/ml, respectively, in plasma).1 It increases plasma glucagon-like peptide-1 (GLP-1; Item No. 24460) and insulin levels and decreases blood glucose levels during an oral glucose challenge in Zucker fa/fa rats when administered at a dose of 10 mg/kg. Alogliptin (2.8 mg/kg per day) decreases plasma DPP-4 activity and increases GLP-1 levels in diabetic ob/ob mice when administered for 29 days.3 Formulations containing alogliptin have been used as an adjunct treatment for type 2 diabetes mellitus.
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
Lee, B., Shi, L., Kassel, D.B., et al. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-
2. Feng, J., Zhang, Z., Wallace, M.B., et al. Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV J. Med Chem. 50(10), 2297-2300 (2007).
Moritoh, Y., Takeuchi, K., Asakawa, T., et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-